Lynx1 Capital Management is a Puerto Rico-based hedge fund managed by Weston Nichols. The firm oversees the Lynx1 Onshore Fund, which focuses on investing in U.S. biotechnology stocks through a long-biased equity strategy.
Dr. Weston Nichols founded Lynx1 Capital in March 2020 and currently serves as its Managing Partner. Before establishing Lynx1 Capital, Dr. Nichols was an analyst at Perceptive Advisors, a life-sciences-focused investment firm, from April 2016 to March 2020. Before that, he worked as an analyst at Balyasny Asset Management from January 2015 to April 2016, and as a biotechnology equity research associate at SunTrust Robinson Humphrey from May 2014 to December 2014. Dr. Nichols holds a B.S. in Biological Engineering from Cornell University and a Ph.D. in Neuroscience from Caltech. His extensive experience as a venture capitalist in the life sciences industry has led to his appointment to the board of directors, where he contributes valuable expertise.
Lynx1 Capital Management is a hedge fund managing discretionary assets totaling $268.3 million, as reported in their Form ADV dated March 26, 2024. Serving four clients, their latest 13F filing for Q1 2024 disclosed $388.2 million in managed 13F securities, with a top 10 holdings concentration of 96.84%. The fund's largest holding is Alpine Immune Sciences Inc., with 2,253,183 shares.
